TCG Crossover (“TCGX”) Announces Oversubscribed $1.3B TCGX Fund III

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--TCG Crossover (“TCGX”) today announced the successful closing of its third fund, TCGX Fund III, with $1.3 billion in capital commitments. Fund III attracted support from both current TCGX investors and new institutional investors, foundations, pensions, and endowments. With the close of Fund III, TCGX has now raised more than $3.1 billion in total capital since its founding in 2021.

“We remain steadfast in our mission to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.”
Share

TCGX Fund III exceeded its initial target, underscoring strong global investor demand. The fundraise marks a significant milestone and is an endorsement of the differentiated strategy and TCGX’s fully flexible mandate to invest across both private and public markets.

“Exceeding our target for Fund III highlights the deep trust and conviction our investors have placed in our team and approach,” said Dr. Chen Yu, Founder and Managing Partner of TCGX. “We remain steadfast in our mission to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.”

“We are grateful to our investors for their support and appreciate the hard work from our portfolio company operators to enable this accomplishment. With Fund III, we look forward to investing in the next generation of biotechs developing transformative therapies for patients,” said Cariad Chester, Managing Partner at TCGX.

As part of this milestone, TCGX is proud to announce the promotion of Giuliano Marostica to Managing Partner. “Giuliano was the first team member to join me at TCGX, and he has played an integral role in building the firm and bringing tremendous value to our portfolio companies,” said Dr. Yu.

CFO/COO Craig Skaling added, “We are fortunate to have built a world-class team at TCGX. Their commitment and talent drive our ability to scale effectively and partner with companies advancing innovative science.”

About TCGX

TCGX is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that improve the lives of patients. TCGX invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. The firm has offices in Palo Alto, San Francisco, and New York City. For more information, please visit www.tcgcrossover.com.

Contacts

Media Contact:
Edward Amorosi, Head of Capital Formation & Investor Relations at TCG Crossover (“TCGX”)
eamorosi@tcgcrossover.com

Industry:

TCG Crossover

Release Summary

Global biotech & life sciences investment firm completes fundraise of its 3rd venture capital fund at its hard cap.

Release Versions

English Spanish Portuguese German French Italian (Summary)Dutch (Summary)Chinese Traditional Chinese Simplified Japanese

Hashtags

Contacts

Media Contact:
Edward Amorosi, Head of Capital Formation & Investor Relations at TCG Crossover (“TCGX”)
eamorosi@tcgcrossover.com

Social Media Profiles

TCGX LinkedIn Company Profile

More News From TCG Crossover

TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine

NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (Nasdaq: TCGX), a special purpose acquisition company (SPAC) sponsored by TCGX, today announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined company will be named “TriGemX Bio, Inc.” (the “Combined Company”...

TCGX Acquisition Corp. II Announces Pricing of $100,000,000 Initial Public Offering

PALO ALTO, Calif.--(BUSINESS WIRE)--TCGX Acquisition Corp. II (the “Company”) announced today that it priced its initial public offering of 10,000,000 Class A ordinary shares at a price of $10.00 per share, for gross proceeds of $100,000,000. Unlike certain other special purpose acquisition company initial public offerings, investors in this offering will not receive warrants that would become exercisable following the completion of the Company’s initial business combination.The Class A ordinary...

TCGX Announces Oversubscribed $600 Million Asia Fund

SHANGHAI & PALO ALTO, Calif.--(BUSINESS WIRE)--TCGX today announced the closing of the TCGX Asia Life Sciences Fund I, an oversubscribed $600 million investment vehicle backed by a diverse group of international institutional investors. The fund will focus on investing in innovative biotechnology companies based in Asia. The fund is a new investment vehicle that will operate separately from, but in close synergy with, TCGX’s Flagship Funds, which focus on biotechnology companies in the United S...

Back to Newsroom